Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01098266
Recruitment Status : Completed
First Posted : April 2, 2010
Results First Posted : September 17, 2019
Last Update Posted : September 17, 2019
Sponsor:
Information provided by (Responsible Party):
MolMed S.p.A.

Brief Summary:
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.

Condition or disease Intervention/treatment Phase
Malignant Pleural Mesothelioma Drug: NGR-hTNF plus Best Investigator's Choice (BIC) Drug: Placebo plus Best Investigator's Choice (BIC) Phase 3

Detailed Description:

Currently, there are no regulatory-approved or widely accepted treatment options for patients failing a standard pemetrexed-based chemotherapy regimen.

For this reason, the best supportive care (BSC) alone might be considered as a standard reference for a randomized phase III trial in this setting.

However, single-agent chemotherapeutic agents (such as doxorubicin,gemcitabine, or vinorelbine) with a well-documented safety profile and antitumor activity are also used in clinical practice.

Therefore, the best investigator's choice (BIC) between either best supportive care alone or combined with a few selected single-agent chemotherapy (including doxorubicin, gemcitabine, or vinorelbine) might be considered as an acceptable reference arm as well in this setting.

The current phase III study aims to show a superior efficacy in terms of overall survival duration of NGR-hTNF 0.8 µg/mq weekly plus BIC versus placebo plus BIC in advanced MPM patients progressing after a standard pemetrexed-based chemotherapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)
Actual Study Start Date : April 12, 2010
Actual Primary Completion Date : April 29, 2014
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma

Arm Intervention/treatment
Experimental: A: NGR-hTNF + BIC
NGR-hTNF plus Best Investigator's Choice
Drug: NGR-hTNF plus Best Investigator's Choice (BIC)
  • NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
  • Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
  • Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:

    1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
    2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
    3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Other Name: NGR-hTNF+BIC

Placebo Comparator: B: Placebo+BIC
Placebo plus Best Investigator's Choice
Drug: Placebo plus Best Investigator's Choice (BIC)
  • Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
  • Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
  • Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:

    1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
    2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
    3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
Other Name: Placebo+BIC




Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assesed up to 48 months ]
    Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: From the date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assessed up to 48 months ]
    Defined as the time from the date of randomization until disease progression, or deathdue to any couse or the last patient was konwn to be alive. Progression is defined usind Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition torelative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. In addition the appearance of one or more new lesions was also considered progression

  2. Disease Control Rate (DCR) [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
    Disease control rate (DCR), defined as the percentage of patients who have a best-response rating of complete or partial response or stable disease, according to MPM-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria

  3. Number of Partecipants With Disease Control for ≥ 6 Months [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
    Measured from the date of randomization until disease progression, or death due to any cause

  4. Number of Partecipants With Adverse Events [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
    All adverse events will be recorded according to CTC version 4.02 (CTC reference: http://ctep.cancer.gov/reporting/ctc.html) on the case report forms (CRFs); the investigator will decide if those events are drug related and his decision will be recorded on the forms for all adverse events.

  5. Time to LCSS Symptomatic Progression [ Time Frame: from the date of randomization to the date of the LCSS assessment on which symptomatic progression was identified, assessed on cycle 2, cycle 4 and cycle 6 (each cycle lasted 21 days) ]
    Quality of life (QoL) assessment was performed by using a questionnaire according to The Lung Cancer Symptom Scale (LCSS) . The LCSS is designed as a disease and site-specific measure of QoL particularly for use in clinical trials. It evaluates six major symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global QoL. Within this trial the questionnaire according to LCSS was only recorded by the patient (patient's scale). QoL assessment was performed by using a questionnaire according to LCSS, which consists of nine 100-mm visual analog scales, with scores reported from 0 to 100 (0 representing the best score). The LCSS subscore is the average symptom burden index computed as the mean score for all six major symptoms. Symptomatic progression was defined as a worsening in the average symptom burden index by 25%.

  6. Evaluation of Medical Care Utilization in the Two Treatment Arms [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
    Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatoid, mixed, or unknown
  • Prior treatment with no more than one systemic pemetrexed-based chemotherapy regimen administered for advanced or metastatic disease. Prior use of a biological agent in combination with a pemetrexed-based regimen and prior administration of intrapleural cytotoxic agents are allowed. Patients who have previously received anthracyclines should not receive doxorubicin
  • ECOG Performance Status 0 - 2
  • Life expectancy of ≥ 12 weeks
  • Adequate baseline bone marrow, hepatic and renal function, defined as follows:

    1. Neutrophils ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; hemoglobin ≥ 9 g/dL
    2. Bilirubin ≤ 1.5 x ULN
    3. AST and/or ALT ≤ 2.5 x ULN in absence of liver metastasis or ≤ 5 x ULN in presence of liver metastasis
    4. Serum creatinine < 1.5 x ULN
  • Measurable or non-measurable disease according to MPM-modified RECIST criteria
  • Patients may have had prior therapy providing the following conditions are met:

    1. Surgery: wash-out period of 14 days
    2. Systemic and radiation anti-tumor therapy: wash-out period of 28 days
  • Patients must give written informed consent to participate in the study

Exclusion Criteria:

  • Patients must not receive any other investigational agents while on study
  • Patients with myocardial infarction within the last six months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
  • Uncontrolled hypertension
  • QTc interval (congenital or acquired) > 450 ms
  • History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy, or history of stroke)
  • Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
  • Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
  • Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01098266


  Hide Study Locations
Locations
Layout table for location information
United States, California
Wilshire Oncology Medical Group
Corona, California, United States, 92879
City of Hope-Comprehensive Cancer Cente
Duarte, California, United States, 91010
United States, Florida
H. Lee Moffitt ancer Center and Research Institute
Tampa, Florida, United States, 33612
United States, Maryland
Johns Hopkins
Baltimore, Maryland, United States, 21231
United States, New York
Columbia University
New York, New York, United States, 10032
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
UTsouthwestern medical center
Dallas, Texas, United States, 75390
Belgium
Antwerp University Hospital
Edegem, Antwerp, Belgium, B-2650
Centre Hospitalier Universitaire de Liège
Liège, Liege, Belgium, 4000
Institut Jules Bordet
Bruxelles, Belgium, 1000
Cliniques Universitarie St. Luc
Bruxelles, Belgium, 1200
Universitair Ziekenhuis
Gent, Belgium, 9000
Canada, Alberta
UAB - Alberta Cancer Board - Cross Cancer Institute
Edmonton, Alberta, Canada, T6G1Z2
Canada, Ontario
University Health Network, Princess Margaret Hospital
Toronto, Ontario, Canada, M5G2C4
Egypt
National Cancer Institute
Cairo, Egypt, 11796
France
Hôpitaux de Marseille Hôpital Nord
Marseille, France, Cedex 20
Ireland
St James's Hospital
Dublin, Ireland
Italy
Ospedale Santo Spirito
Casale Monferrato, Alessandria, Italy, 15033
Azienda Ospedaliera Universitaria San Luigi Gonzaga
Orbassano, Torino, Italy, 10043
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Alessandria, Italy, 15100
Centro di Riferimento Oncologico
Aviano, Italy
Ospedale Valduce
Como, Italy
Azienda Ospedaliero-Universitaria Careggi di Firenze
Firenze, Italy
Istituto Nazionale per la Ricerca sul Cancro
Genoa, Italy, 16132
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST
Meldola, Italy, 47014
Fondazione San Raffaele del Monte Tabor
Milan, Italy, 20132
Azienda Ospedaliera San Gerardo
Monza, Italy, 20052
Istituto Oncologico Veneto
Padova, Italy
Azienda Ospedaliero Universitaria di Parma
Parma, Italy
Azienda Unità Sanitaria locale di Ravenna
Ravenna, Italy, 48100
A.O. Salvini Garbagnate, Ospedale di Rho
Rho, Italy
Azienda Ospedaliera Senese
Siena, Italy, 53100
Netherlands
St. Jansdal Hospital
Harderwijk, Gelderland, Netherlands, 3840
St. Antonius Hospital
Nieuwegein, Utrecht, Netherlands, 3435
Poland
Medical University of Gdansk
Gdansk, Poland, 80211
Maria Sklodowska Memorial Cancer Center and Institute of Oncology
Warsaw, Poland, 02-781
Spain
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain, 08916
Hospital Vall d'Hebron
Barcelona, Spain, 08035
Sweden
The University Hospital
Linkoping, Sweden, 581 85
United Kingdom
Chest Clinic, Wythenshawe Hospital
Manchester, Greater Manchester, United Kingdom, M23 9LT
Kent Oncology Centre Maidstone Hospital
Maidstone, Kent, United Kingdom, ME16 9QQ
University Hospitals of Leicester
Leicester, Leicestershire, United Kingdom, LE0116
Mount Vernon Cancer Centre
Middlesex, Northwood, United Kingdom, HA6 2RN
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 2XU
The Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom, G12
The Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Castle Hill Hospital
Cottingham, Yorkshire, United Kingdom, HU16 5JQ
Guy's Hospital
London, United Kingdom, SE1 9RT
The Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Sponsors and Collaborators
MolMed S.p.A.
Investigators
Layout table for investigator information
Study Director: Antonio Lambiase, MD MolMed S.p.A.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: MolMed S.p.A.
ClinicalTrials.gov Identifier: NCT01098266     History of Changes
Other Study ID Numbers: NGR015
2009-016879-29 ( EudraCT Number )
First Posted: April 2, 2010    Key Record Dates
Results First Posted: September 17, 2019
Last Update Posted: September 17, 2019
Last Verified: August 2019
Keywords provided by MolMed S.p.A.:
MPM
NGR-hTNF
NGR-hTNF plus BIC
Randomized double-blind phase III study
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial